Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to the Letter to the Editor: Cumulative LDL-C and Lipoprotein(a) in Elderly Patients with Hyperlipidemia: Methodological Considerations and Clinical Implications.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2026
Same author

Lipoprotein(a) and Cumulative Low-Density Lipoprotein Cholesterol as Predictors of Coronary Artery Disease in Statin-Naïve Elderly Individuals with Hyperlipidemia.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2026
Same author

Reply to Letter to the Editor: "Comments on Nonsustained Atrial Fibrillation and Stroke Risk: Methodological and Interpretive Considerations".

Anatolian journal of cardiology·2025
Same author

Reply to Letter to the Editor: "Methodological Considerations in Non-Sustained Atrial Fibrillation and Stroke Risk".

Anatolian journal of cardiology·2025
Same author

Association Between HNP1-3 and Atherosclerotic Plaque Burden in Subclinical Atherosclerosis and the Mediating Effect of PCSK9.

Clinical and translational science·2025
Same author

Reply to Letter to the Editor: "Rethinking Risk Stratification in Emergency Department Patients with Nonsustained Atrial Fibrillation".

Anatolian journal of cardiology·2025
Same journal

Endothelin-Dependent Myocardial Dysfunction in an Experimental Endotoxic Shock Model.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2026
Same journal

Subclinical Cardiac Dysfunction in Children with Iron Deficiency Anemia Assessed by Tissue Doppler and Speckle-Tracking Echocardiography-Uncorrected Proof.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2026
Same journal

Reply to the Letter to the Editor: A Critical Appraisal of Drug-Coated Balloon Use in STEMI: Biological Context, Cohort Heterogeneity, and Strategy Definition.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2026
Same journal

Reply to the Letter to the Editor: Assessing the Predictive Value of Kolmogorov-Arnold Networks for the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: A Comparative Machine Learning Study.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2026
Same journal

High Discriminative Performance Without Clinical Readiness: Methodological Gaps in Machine Learning-Based Prediction of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2026
Same journal

A Critical Appraisal of Drug-Coated Balloon Use in STEMI: Biological Context, Cohort Heterogeneity, and Strategy Definition.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

[Renin and the heart].

Dilek Ural1, Metin Cetin

  • 1Department of Cardiology, Medicine Faculty of Kocaeli University, Kocaeli, Turkey. dilekural@gmail.com

Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
|December 19, 2009
PubMed
Summary
This summary is machine-generated.

Direct renin inhibitor aliskiren reduces plasma renin activity, a cardiovascular risk factor, offering a novel approach to managing hypertension and cardiovascular diseases beyond blood pressure reduction.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Experiment Videos

Last Updated: Jun 17, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Context:

  • The renin-angiotensin system (RAS) is crucial in cardiovascular regulation.
  • RAS inhibition lowers blood pressure but can increase plasma renin activity, posing residual cardiovascular risk.
  • Existing treatments like ACE inhibitors and ARBs do not reduce plasma renin activity.

Purpose:

  • To highlight aliskiren as a direct renin inhibitor.
  • To differentiate aliskiren's mechanism from ACE inhibitors and ARBs.
  • To discuss aliskiren's potential in cardiovascular disease management.

Summary:

  • Aliskiren uniquely reduces plasma renin activity, an independent cardiovascular risk factor.
  • Unlike ACE inhibitors and ARBs, aliskiren addresses the negative feedback issue in RAS blockade.
  • Its efficacy and safety in hypertension are established, with ongoing research into its effects on cardiovascular mortality and morbidity.

Impact:

  • Aliskiren offers a new therapeutic option for RAS blockade.
  • It may mitigate residual cardiovascular risk associated with traditional RAS inhibitors.
  • Further research is investigating its comprehensive impact on cardiovascular outcomes.